Abstract:Aims and objectives: The transmission pattern of drug resistant Mycobacterium tuberculosis (MTB) might vary due to the differences in geographic features, socio-economic development and TB epidemic in specific areas and populations. This might also reflect how effectively a TB control program would work. This study aimed to investigate the transmission pattern of drug resistant TB, especially multidrug-resistant (MDR)-TB, and to discuss its implications for an effective TB control program in rural China. Methods: Applying a combination of conventional epidemiology with MIRU-VNTR-based genotyping and DNA sequencing, a descriptive cross-sectional study was performed in two Chinese rural counties: DQ, a long-term DOTS-covered county, and GY, where the DOTS program was launched 11 years later than DQ. Results: In total, 238 bacteriologic confirmed pulmonary TB patients from DQ and 393 from GY diagnosed between 2008 and 2011 were recruited in the study. Of the 631 isolates, 220 (34.9%) were resistant to at least one anti-TB drug, including 95 (15.1%) simultaneously resistant to isoniazid and rifampicin or MDR, albeit with the similar distribution between DQ and GY (32/238 vs. 63/393; p, 0.378). The MIRU-VNTR genotyping revealed 35 isolates from DQ and 86 from GY exhibited 15 and 32 clustering patterns with four patterns shared between two counties. Compared with GY county, DQ had a significantly lower clustering proportion in MTB isolates susceptible to first-line drugs (25/167 vs. 46/198; p, 0.047) and total drug resistant TB isolates (12/71 vs. 44/149; p, 0.044), but a similar clustering proportion in MDR-TB isolates (8/32 vs. 18/63; p, 0.712). A significant higher clustering proportion was observed in the previously treated patients in both counties, but in the sputum smear-positive patients with cavitaries only in GY. Comparing the previously treated patients between the two counties, the proportion of MDR-TB and clustering proportion exhibited a similar distribution, while the average age of previously treated patients in DQ is significantly older than that in GY. Conclusions: A lower proportion of recent transmissions was observed in the county with long-term DOTS implementation. However, DOTS itself might not have worked enough on blocking the recent transmission of MDR-TB. This observation suggests the urgent needs of implementing the Stop-TB strategies; in particular, accelerating the use of rapid molecularbasedTBdiagnosisand drug susceptibility testing, providing active case findings in a high risk population of MDR-TB and enhancing infection control in high MDR-TB burden countries.

Improved Treatment Outcome of Multidrug-Resistant Tuberculosis with the Use of a Rapid Molecular Test to Detect Drug Resistance in China.

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China

Performance of Biochip System in Detecting Drug Resistant and Multidrug-Resistant Tuberculosis Using Sputum Collected from Multiple Clinical Settings in Zhejiang, China.

Introducing Molecular Testing of Pyrazinamide Susceptibility Improves Multidrug-Resistant Tuberculosis Treatment Outcomes: a Prospective Cohort Study.

Multi-center Evaluation of GenoType MTBDRsl Line Probe Assay for Rapid Detection of Pre-Xdr and XDR Mycobacterium Tuberculosis in China

Treatment Quality and Outcome for Multidrug-Resistant Tuberculosis Patients in Four Regions of China: a Cohort Study.

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

Evaluation of the Microscopic Observation Drug Susceptibility Assay for the Rapid Detection of MDR-TB and XDR-TB in China: a Prospective Multicentre Study

Comparative Utility of Genetic Determinants of Drug Resistance and Phenotypic Drug Susceptibility Profiling in Predicting Clinical Outcomes in Patients with Multidrug-Resistant Mycobacterium Tuberculosis

Additional Drug Resistance for Mycobacterium Tuberculosis During Turnaround Time for Drug-Susceptibility Testing in China: A Multicenter Observational Cohort Study

Direct Tuberculosis Drug Susceptibility Testing: Time-Saving and Cost-Effective in Detecting Mdr-Tb

MTBDRplus results correlate with treatment outcome in previously treated tuberculosis patients.

Evaluation of the GenoType® MTBDRplus Assay and Identification of a Rare Mutation for Improving MDR-TB Detection

Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients.

Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis

Accuracy of Molecular Diagnostic Tests for Drug-Resistant Tuberculosis Detection in China: a Systematic Review

Selection of Mutations to Detect Multidrug-Resistant Mycobacterium Tuberculosis Strains in Shanghai, China

Effect of the Xpert MTB/RIF on the Detection of Pulmonary Tuberculosis Cases and Rifampicin Resistance in Shanghai, China

Molecular Epidemiology of TB – Its Impact on Multidrug-Resistant Tuberculosis Control in China

Proficiency of phenotypic drug susceptibility testing for Mycobacterium tuberculosis in China, 2008–2021